Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder

  • Technology appraisal guidance
  • TA292
  • Published: 
Download guidance (PDF)

9 Sources of evidence considered by the Committee

A. The Evidence Review Group (ERG) report for this appraisal was prepared by School of Health and Related Research (ScHARR), The University of Sheffield:

  • Uttley L, Kearns B, Stevenson M et al. Aripiprazole for the treatment and prevention of acute manic and mixed episodes in bipolar disorder in children and adolescents. A Single Technology Appraisal. School of Health and Related Research (ScHARR), The University of Sheffield, March 2013.

B. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope. Organisations listed in I were also invited to make written submissions. Organisations listed in II gave their expert views on aripiprazole by providing a written statement to the Committee. Organisations listed in I, II and III have the opportunity to appeal against the final appraisal determination.

I. Manufacturer/sponsor

  • Otsuka Pharmaceuticals (aripiprazole)

II. Professional/specialist and patient/carer groups:

  • British Association for Psychopharmacology

  • Royal College of Nursing

  • Royal College of Paediatrics and Child Health

  • Royal College of Pathologists

  • Royal College of Psychiatrists

  • United Kingdom Clinical Pharmacy Association

III. Other consultees:

  • Department of Health

  • Welsh Government

IV. Commentator organisations (did not provide written evidence and without the right of appeal):

  • Commissioning Support Appraisals Service

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Healthcare Improvement Scotland

  • National Collaborating Centre for Mental Health (NCCMH)

  • National Institute for Health Research Health Technology Assessment Programme

  • School of Health & Related Research Sheffield (ScHARR)

C. The following individuals were selected from clinical specialist and patient expert nominations from the consultees and commentators. They gave their expert personal view on aripiprazole by providing oral evidence to the Committee.

  • Dr Anthony James, Consultant Child and Adolescent Psychiatrist, nominated by organisation representing Royal College of Psychiatrists – clinical specialist

  • Dr David Coghill, Reader in child and adolescent psychiatry, University of Dundee, nominated by organisation representing Royal College of Psychiatrists and British Association for Psychopharmacology – clinical specialist

D. Representatives from the following manufacturer/sponsor attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Otsuka Pharmaceuticals